thalassemia major
Conditions
Interventions
control group:Busulfan+fludarabine+cyclophosphamiade+antithymocyte globulin(10mg/kg)
experimental group :Busulfan+fludarabine+cyclophosphamiade+antithymocyte globulin(8mg/kg)
Sponsors
First Affilited Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age: 2 to 18 years old; 2. Gender: Male or female; 3. Thalassemia major; 4. HLA-matched related hematopoietic stem cell transplantation; 5. no sereve infection; 6. In good general condition, ECOG score less than 1; 7. Normal heart function: ejection fraction more than 50%; 8. Normal liver and renal function: Serum bilirubin less than 35umol/L, AST/ALT less than 2 times the upper limit, serum creatinine under 2 times the upper limit; 9. Enrolled subjects or their families signed informed consent.
Exclusion criteria
Exclusion criteria: 1. severe infection uncontrolled before transplantation; 2. severe allergic on Antithymocyte globulin (anaphylactic shock or laryngeal edema); 3. unrelated allogeneic hematopoietic stem cell transplantation;Hyplotype allogeneic hematopoietic stem cell transplantation; second transplantation, reduced-intensisty transplantation; 4. Cardiac dysfunction (ejection fraction less than 50%); 5. Renal insufficiency (serum creatinine more than 130umol/L); 6. Hepatic dysfunction (total bilirubin more than 34umol/L, ALT, AST more than 2 times the upper limit of normal); 7. Previously history of allogeneic hematopoietic stem cell transplantation; 8. Other circumstances which do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| over-survival;disease-free survival; | — |
Countries
China
Contacts
Public ContactYongrong Lai
Outcome results
None listed